The European Medicines Agency’s CHMP has recommended approving Novo Nordisk’s hemophilia A preventive drug, alongside positive opinions for seven other medicines and 11 label expansions. The CHMP’s package covers both new therapies and updates to existing products, moving the medicines closer to final EU authorization. Among the recommendations highlighted in the CHMP list are two new ovarian cancer therapies and what is described as a potential first oral treatment option for hidradenitis suppurativa. The month’s slate also includes additional medicines across other therapeutic areas. CHMP recommendations do not represent the final EU step, but they are a key milestone that typically precedes European Commission approval. For biotech and pharma, the decision can quickly reshape competitive positioning around access and treatment guidelines. Label expansions matter for companies because they often broaden eligible patient populations or add new indications, potentially expanding prescribing and revenue opportunity well beyond the initial approval scope.